EPITERO 50MG INJ VIAL

About

EPITERO 50MG INJ VIAL contains Epirubicin, an anthracycline topoisomerase II inhibitor, which is a type of cytotoxic chemotherapy drug. It works by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, all of which lead to DNA damage and inhibition of nucleic acid synthesis. This ultimately results in the death of rapidly dividing cancer cells. Epirubicin is used in the treatment of various solid tumors.

Its broad spectrum of activity makes it a valuable agent in the management of breast cancer, ovarian cancer, gastric cancer, and lymphomas. Epirubicin is administered intravenously and is often used as part of combination chemotherapy regimens. Its efficacy stems from its ability to disrupt the fundamental processes of cell division and replication in malignant cells, thereby controlling tumor growth and progression.

Uses

• Treatment of breast cancer (adjuvant and metastatic).
• Treatment of ovarian cancer.
• Treatment of gastric cancer.
• Treatment of lymphomas and soft tissue sarcomas.

Directions For Use

This medication is administered intravenously by a healthcare professional. The dosage and schedule are determined by your physician based on your cancer type and overall health.

Benefits

• Effective against a wide range of solid tumors.
• Can be used as part of combination chemotherapy regimens.
• Improves disease-free survival in early-stage cancers.
• Reduces tumor burden in advanced cancers.
• Well-established efficacy in breast cancer treatment.
• Contributes to overall survival in eligible patients.

Side Effects

• Nausea and vomiting
• Hair loss (alopecia)
• Myelosuppression (low blood counts)
• Stomatitis (mouth sores)
• Diarrhea
• Fatigue
• Cardiotoxicity (e.g., heart failure)
• Red urine (due to drug color)
• Injection site reactions
• Amenorrhea (absence of menstruation)
• Skin hyperpigmentation
• Secondary malignancies (rare)

Safety Measures

• Alcohol - Avoid alcohol during treatment as it can exacerbate gastrointestinal side effects and potentially interact with liver metabolism.
• Pregnancy - Epirubicin can cause severe fetal harm. It is contraindicated in pregnancy. Effective contraception must be used during and for a period after treatment.
• Breastfeeding - Epirubicin is excreted in human milk. Breastfeeding is contraindicated during treatment due to the potential for serious adverse reactions in the infant.
• Liver - Use with extreme caution in patients with hepatic impairment. Dose reduction is necessary for elevated bilirubin or AST levels. Liver function must be closely monitored.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment, but caution is advised. Renal function should be monitored.
• Lung - Rare cases of interstitial pneumonitis have been reported. Patients should be monitored for new or worsening pulmonary symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.